ADI-002

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug NameADI-002
Drug Alias NameADI-002 GPC3 gamma-delta CAR-TADI0-002ADI-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Source of cells > Monocyte-derived +[5] 
Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitorsInterleukin-15 stimulants
TargetsGlypican-3Interleukin-15
Therapy Area/IndicationsSolid tumoursCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdicet Bio IncRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals IncAdicet Bio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A